2Soussi T,Legros Y, Lubin R, et al. Multifactorial analysis of p53 alteration in human cancer [J]. Int I Cancer, 1994,57 (1):1-9.
3Chang F,Syrjanen S,Syrjanen K, et al. Implications of the p53 turnout-suppressor gene in clinical ontology []]. J Clin Oncol,1995,13(4): 1009-1022.
4Von Brevern MC, Hollstein MC,Cawley HM, et al. Circulating anti-p53 antibodies in esoplageal cancer patients are found predominantly individuals with p53 core domain mutations in their tumors [J]. Cancer Res,1996,56(5):4917- 4921.
5Soussi T. P53 antibodies in the sera of patients with various type of cancer: a review[J]. Cancer Res, 2000,60 (7) : 1777-1788.
6Shiota G, Ishida M, Noguchi H, et al. Clinical significance of serum p53 antibody inpatients with gastric cancer[J]. Res Commun Mol Pathol Pharmacol, 1998,99 (1) : 41-51.
7Muller M,Volkmann M,Zentgraf H, et al. Clinical implications of p53 tumor-suppressor gene [J]. N Engl J Med, 1994, 330(12):865.
8Wtarl P, Weigmann F, Meye A, et al. Detection of p53 autoantibodys in sera of gastric cancer patients and prognostic relevance [J]. Scand J Gastroentrol, 1997,32 (11): 1147 - 1151.
9Wu CW,Lin YU,Chen GD, et al. Serum anti-p53 antibodies in gastric adenocareinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade[J]. Br J Cancer,1999,80(3-4) :483-488.
9Ohkuma K, Okada M, Murayama H, et al. Association of Helicobacter pylori infection with atrophic gastritis and intestinal metaplasia [J]. J Gastroenterol Hepatol, 2000,15(10):1105-1112.
10Lee SA, Kang D, Shim KN, et al, Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer [J].J Epidemiol,2003,13(3):162-168.
